Cerestim is developing an integrated healthcare solution for the treatment of brain disorders. Our technology: transcranial electrical stimulation (TES) will be initially targeted at the condition of Treatment Resistant Depression (TRD) which affects over 30m people globally and over 1m in the UK.
Current treatments are antidepressants, which only work for 45% of patients; talking therapies which are only useful for mild depression; and electroconvulsive therapy (ECT), which is expensive and has serious side effects. New modalities are required to improve patient outcomes, lower side effects and raise efficiency. Our wearable headset is internet-connected and designed for use at home. It provides real-time treatment and compliance data to clinicians and will increase clinical capacity in secondary care.
Our business model generates revenues from sales of device headsets; sales of electrodes per treatment session; cloud software services; and big data analytics. We have a first class and internationally experienced team who are in the process of raising Series A funding to complete product prototyping and conduct a first in-patient clinical study.